The approval was based on the phase III randomized active-controlled three-arm COLUMBUS trial, which evaluated the combined encorafenib–binimetinib vs. encorafenib alone or vemurafenib alone in patients with BRAF-mutated unresectable or metastatic melanoma [31]. The gene discussed is BRAF; the disease is metastatic melanoma.